Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Effect of Metformin on Prostate Specific Antigen Doubling Time

NCT02176161 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT02176161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02176161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Effect of Metformin on Prostate Specific Antigen Doubling Time
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2014
Completion date
July 21, 2021
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate cancer recurrent